Reviewer #1 (Remarks to the Author):
rHDL particles and effective ATF5 suppression by siRNA in vitro are well designed and executed. The evidence that macropinocytosis plays a key role in the process is also convincing. The endogenous Ras and Rac pathways are known to play an essential role in the control of macropinocytosis in both normal and transformed cells, so it is not surprising that knockdown of Ras expression results in reduced uptake of CaP-rHDL nanoparticles. However, the claim that that such nanoparticles represent a specific therapeutic approach for selective targeting of tumors driven by activated Ras is confusing, and the studies fall short of demonstrating this. The problem is, in part, related to the authors' use of the terms "Ras-activated" glioblastoma and "Rastransformed cell line". Activating mutations in Ras are rare in human GBM, and the majority of the studies in this report were performed with the C6 rat glioma cell line, which does not harbor Ras mutations and thus is not a "Ras-activated cell line". It is true that expression of endogenous Ras protein is relatively high in these cells compared with normal astrocytes but this is not the same as a "Ras-activated" tumor where Ras mutation (e.g., V12) results in constitutive activation of Ras pathways and is a driver of tumorigenesis and tumor progression.
Specific Comments: 1) Measurements of total endogenous Ras protein expression levels ( Fig. 5a ) do not necessarily indicate that Ras is "hyperactivated". Determination of the percentage of activated Ras (e.g., by G-LISA Ras activation assays) would be required to draw this conclusion.
2) The conclusion that CaP-rHDL nanoparticles "penetrated deep and distributed extensive(ly) in the C6 glioblastoma spheroids" (pg 16) seems inconsistent with the confocal images in Supplementary Fig. 2 , which show most of the DiI-labeled CaP-rHDL concentrated around the periphery of the spheroids. Regarding the same point, in Fig. 5b , the images of patient-derived spheroids appear to be whole mounts, so it is not clear whether the fluorescent cells are mostly on the surface or the interior.
3) The small sizes of some of the illustrations, particularly in the complex figures, make it impossible to see if the conclusions are supported. For example, in Fig. 8d , the authors conclude that treatment with ATF5 siRNA "led to hyperchromatism of the cell nuclei". That panel should be moved to the supplementary data and expanded so that nuclear morphology can be easily assessed. 4) In Fig. 8e , we are shown one spheroid for each condition evidence that anti-ATF5-CaP-rHDL nanoparticles inhibit growth/viability of C6 spheroids. This conclusion needs to be supported by quantitative data such as average spheroid diameter or volume, with an appropriate n and statistical analysis. 5) The argument that the increased apoptosis ( Fig. 9 ) and the improved survival ( Fig. 10 ) of mice treated with anti-ATF5 nanoparticles is specifically related to suppression of ATF5 would be strengthened by IF or WB results demonstrating that ATF5 is suppressed in the tumor tissue. 6) The paper contains numerous grammatical and typographical errors throughout.
Below is a detailed description of our revision according to the review comments.
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Reviewer: 1

Comments:
This manuscript reports the development of a biomimetic lipoprotein nanoparticle (CaP-rHDL) for the efficient delivery of siRNA as the target treatment of Ras-activated brain cancer. In this work, the authors carefully characterized the Ras-activation dependency of the macropinocytosis-mediated cellular uptake of the CaP-rHDL in both glioblastoma cell line and patient-derived glioblastoma. They further demonstrated the anti-glioma activity of ATF5 siRNA-loaded CaP-rHDL both in vitro and in vivo, resulting in remarkable RNA-interfering efficiency and increased apoptosis at a low siRNA dose (0.36mg/kg). Ras pathway plays essential role in malignant transformation and is an attractive target for cancer therapies. This strategy of targeting the macropinocytosis caused by Ras activation is highly novel and could provide powerful nanoparticle-based treatment strategy for Ras-activated cancers. In my opinion, this study is potentially very exciting and is a rather comprehensive work that could be considered for publication on Nature Communications after addressing following concerns.
1. The stability of control particle, CaP-LNC for in vivo study could contribute to the significant low uptake of CaP-LNC in tumor compared with CaP-rHDL, rather than the less targeting effect assumption made by authors (Fig 6 discussion) Table 1 
Please correct some inconsistent dye labeling in Fig 6 (DiR-labeled) vs in the text (DiI-labeled). The explanation for switching DiI labeling (in vitro study) to DiR
labeling (in vivo study) should also be given.
Response: Thanks for the suggestion and sorry for the confusion. In our study, DiI-labeling was used for both in vitro cellular uptake study ( 
Reviewer: 2
Comments:
Brain tumor delivery is a significant concern. The studies involve a potential improvement in the specificity of delivery based on a system specifically geared towards ras activated cells. The initial phases of the development are interesting, but the biologic aspects of the studies are relatively weak and would benefit from substantial additional effort. In addition, the data are poorly presented with substantial data potentially better presented as data not shown or in the supplemental data. Response: Great points. We agree with the reviewer that more models will make the study more reliable. C6 cell, as a classical rat glioma cell line with close relation with RAS pathway for cell proliferation 6 (Fig. 4 and supplementary Fig. 2-3 ).
The authors make assumptions regarding ras activity based on shRNA against three Ras family members and immunoblots. This is inadequate. The measurement of ras activity, not ras protein expression, should be performed with every model.
Response
To determine whether the cancer cell-targeting delivery strategy can be translated into a human system, we further investigated the cellular uptake of 6f-h, Fig. 8e-f, Fig. 9b-c, Fig. 9e and supplementary Fig. 2-4 .
The glioma initiating cells (GICs) lack any kind of validation. To claim GICs, it is essential to perform in vivo and in vitro analysis. The optimal approach would involve the separation of stem-like and differentiated progeny and tumor initiation in vivo with in vitro limiting dilution studies.
Response: Good suggestion. According to the reviewer's suggestion, data about Fig. 9c) . In addition, the long term effect of ATF5-CaP-rHDL treatment was reflected by the survival in both animal models following four or five injections (Fig. 9d-e) . According to the reviewer's suggestion, in this revised manuscript, additional cell models and animal model bearing patient-derived glioblastoma were further used for studying the mechanism and evaluating the efficacy of CaP-rHDL-mediated glioblastoma-targeting siRNA delivery (Fig. 4, 5, 6, 8 and 9 ).
The shRNA studies for each Ras family member is somewhat concerning. Having the same response for all the Ras members suggests a lack of specificity in the effects.
It would be useful to document the
Hope all our revisions and responses will be satisfactory and this revised version will be acceptable for publication in Nature Communications.
Reviewer: 3
Summary:
In this manuscript the authors provide evidence that ApoE-rHDL nanoparticles (Fig. 4-5) . In addition, reducing Ras activity by knocking down Ras expression also significantly inhibited the macropinocytosis-dependent cellular uptake of CaP-rHDL (Fig. 4-5 and supplementary Fig. 2-3 Response: Good points. We agree with the reviewer that our previous conclusion that CaP-rHDL nanoparticles "penetrated deep and distributed extensive in the C6 glioblastoma spheroids" seems inconsistent with the confocal images in Supplementary Fig. 2 . Indeed, when the tumor spheroids grow up to a certain extent, necrotic cores occur at the center of the spheroids. This could be the major reason why most of the DiI-labeled NP concentrated around the periphery of the spheroids as demonstrated previously. Reviewer 2 also points out that this 3D C6 glioblastoma spheroid is not properly designed. Therefore, we deleted the related data derived from C6 glioblastoma spheroids. In this revised manuscript, the high permeability of CaP-rHDL was reflected by its deep penetration and extensive distribution at the glioblastoma sites in the brain of the tumor-bearing animals ( Fig. 6 and Supplementary Fig. 5 ). In the case of patient-derived GICs spheroids, where less necrotic cores occur, as shown in Fig. 5b and   supplementary video 1-2 , deep penetration of CaP-rHDL within the spheroids was witnessed.
3 5) The argument that the increased apoptosis (Fig. 9 ) and the improved survival ( Response: Thanks for the suggestion. Accordingly, we examined the level of ATF5 at the tumor site by western blot, finding that compared with saline, ATF5-CaP-rHDL suppressed ATF5 expression by 80% (Fig. 9b) . Such description was also added in the revised manuscript, please see Fig. 9b and Line 501-503.
6) The paper contains numerous grammatical and typographical errors throughout.
Response: Thanks for the suggestion. The grammatical and typographical errors have been corrected. We hope this revised version could be much more fluent and neat.
